Review



human liver cancer hepg2  (ATCC)


Bioz Verified Symbol ATCC is a verified supplier
Bioz Manufacturer Symbol ATCC manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 99
      Buy from Supplier

    Structured Review

    ATCC human liver cancer hepg2
    Changes in the basal autophagy flux in different cancer cell lines in response to doxorubicin. <t>HepG2,</t> MCF-7, MDA-MB-231, U87 and normal fibroblast cells were treated with different concentrations of doxorubicin chemotherapy. The level of expression of ULK1, USP20, and P62 was determined via reverse transcription-quantitative PCR. (A-C) Relative expression of ULK1, USP20 and P62 in HepG2 cells. (D-F) Relative expression of ULK1, USP20 and P62 in MCF-7 breast cancer cells. (G-I) Relative expression of ULK1, USP20 and P62 in MDA-MB-231 breast cancer cells. (J-L) Relative expression of ULK1, USP20 and P62 in U87 cells. (M-O) Relative expression of ULK1, USP20 and P62 in normal fibroblast cells. Three repeats were considered for each treatment group. Data are presented as the mean ± SEM. Statistical significance was indicated as * P<0.05, ** P<0.01, *** P<0.001 and **** P<0.0001 (one-way ANOVA followed by Bonferroni's multiple comparisons post hoc test). ULK1, Unc-51-like kinase 1.
    Human Liver Cancer Hepg2, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 31694 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human liver cancer hepg2/product/ATCC
    Average 99 stars, based on 31694 article reviews
    human liver cancer hepg2 - by Bioz Stars, 2026-04
    99/100 stars

    Images

    1) Product Images from "Targeting ULK1 and USP20 to modulate autophagy and chemosensitivity in cancer cell lines"

    Article Title: Targeting ULK1 and USP20 to modulate autophagy and chemosensitivity in cancer cell lines

    Journal: Biomedical Reports

    doi: 10.3892/br.2026.2124

    Changes in the basal autophagy flux in different cancer cell lines in response to doxorubicin. HepG2, MCF-7, MDA-MB-231, U87 and normal fibroblast cells were treated with different concentrations of doxorubicin chemotherapy. The level of expression of ULK1, USP20, and P62 was determined via reverse transcription-quantitative PCR. (A-C) Relative expression of ULK1, USP20 and P62 in HepG2 cells. (D-F) Relative expression of ULK1, USP20 and P62 in MCF-7 breast cancer cells. (G-I) Relative expression of ULK1, USP20 and P62 in MDA-MB-231 breast cancer cells. (J-L) Relative expression of ULK1, USP20 and P62 in U87 cells. (M-O) Relative expression of ULK1, USP20 and P62 in normal fibroblast cells. Three repeats were considered for each treatment group. Data are presented as the mean ± SEM. Statistical significance was indicated as * P<0.05, ** P<0.01, *** P<0.001 and **** P<0.0001 (one-way ANOVA followed by Bonferroni's multiple comparisons post hoc test). ULK1, Unc-51-like kinase 1.
    Figure Legend Snippet: Changes in the basal autophagy flux in different cancer cell lines in response to doxorubicin. HepG2, MCF-7, MDA-MB-231, U87 and normal fibroblast cells were treated with different concentrations of doxorubicin chemotherapy. The level of expression of ULK1, USP20, and P62 was determined via reverse transcription-quantitative PCR. (A-C) Relative expression of ULK1, USP20 and P62 in HepG2 cells. (D-F) Relative expression of ULK1, USP20 and P62 in MCF-7 breast cancer cells. (G-I) Relative expression of ULK1, USP20 and P62 in MDA-MB-231 breast cancer cells. (J-L) Relative expression of ULK1, USP20 and P62 in U87 cells. (M-O) Relative expression of ULK1, USP20 and P62 in normal fibroblast cells. Three repeats were considered for each treatment group. Data are presented as the mean ± SEM. Statistical significance was indicated as * P<0.05, ** P<0.01, *** P<0.001 and **** P<0.0001 (one-way ANOVA followed by Bonferroni's multiple comparisons post hoc test). ULK1, Unc-51-like kinase 1.

    Techniques Used: Expressing, Reverse Transcription, Real-time Polymerase Chain Reaction



    Similar Products

    human liver cancer hepg2  (ATCC)
    99
    ATCC human liver cancer hepg2
    Changes in the basal autophagy flux in different cancer cell lines in response to doxorubicin. <t>HepG2,</t> MCF-7, MDA-MB-231, U87 and normal fibroblast cells were treated with different concentrations of doxorubicin chemotherapy. The level of expression of ULK1, USP20, and P62 was determined via reverse transcription-quantitative PCR. (A-C) Relative expression of ULK1, USP20 and P62 in HepG2 cells. (D-F) Relative expression of ULK1, USP20 and P62 in MCF-7 breast cancer cells. (G-I) Relative expression of ULK1, USP20 and P62 in MDA-MB-231 breast cancer cells. (J-L) Relative expression of ULK1, USP20 and P62 in U87 cells. (M-O) Relative expression of ULK1, USP20 and P62 in normal fibroblast cells. Three repeats were considered for each treatment group. Data are presented as the mean ± SEM. Statistical significance was indicated as * P<0.05, ** P<0.01, *** P<0.001 and **** P<0.0001 (one-way ANOVA followed by Bonferroni's multiple comparisons post hoc test). ULK1, Unc-51-like kinase 1.
    Human Liver Cancer Hepg2, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human liver cancer hepg2/product/ATCC
    Average 99 stars, based on 1 article reviews
    human liver cancer hepg2 - by Bioz Stars, 2026-04
    99/100 stars
    		  Buy from Supplier
    human hepg2 liver cancer  (ATCC)
    99
    ATCC human hepg2 liver cancer
    Changes in the basal autophagy flux in different cancer cell lines in response to doxorubicin. <t>HepG2,</t> MCF-7, MDA-MB-231, U87 and normal fibroblast cells were treated with different concentrations of doxorubicin chemotherapy. The level of expression of ULK1, USP20, and P62 was determined via reverse transcription-quantitative PCR. (A-C) Relative expression of ULK1, USP20 and P62 in HepG2 cells. (D-F) Relative expression of ULK1, USP20 and P62 in MCF-7 breast cancer cells. (G-I) Relative expression of ULK1, USP20 and P62 in MDA-MB-231 breast cancer cells. (J-L) Relative expression of ULK1, USP20 and P62 in U87 cells. (M-O) Relative expression of ULK1, USP20 and P62 in normal fibroblast cells. Three repeats were considered for each treatment group. Data are presented as the mean ± SEM. Statistical significance was indicated as * P<0.05, ** P<0.01, *** P<0.001 and **** P<0.0001 (one-way ANOVA followed by Bonferroni's multiple comparisons post hoc test). ULK1, Unc-51-like kinase 1.
    Human Hepg2 Liver Cancer, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human hepg2 liver cancer/product/ATCC
    Average 99 stars, based on 1 article reviews
    human hepg2 liver cancer - by Bioz Stars, 2026-04
    99/100 stars
    		  Buy from Supplier
    hepg2 human liver cancer cell line  (ATCC)
    99
    ATCC hepg2 human liver cancer cell line
    Changes in the basal autophagy flux in different cancer cell lines in response to doxorubicin. <t>HepG2,</t> MCF-7, MDA-MB-231, U87 and normal fibroblast cells were treated with different concentrations of doxorubicin chemotherapy. The level of expression of ULK1, USP20, and P62 was determined via reverse transcription-quantitative PCR. (A-C) Relative expression of ULK1, USP20 and P62 in HepG2 cells. (D-F) Relative expression of ULK1, USP20 and P62 in MCF-7 breast cancer cells. (G-I) Relative expression of ULK1, USP20 and P62 in MDA-MB-231 breast cancer cells. (J-L) Relative expression of ULK1, USP20 and P62 in U87 cells. (M-O) Relative expression of ULK1, USP20 and P62 in normal fibroblast cells. Three repeats were considered for each treatment group. Data are presented as the mean ± SEM. Statistical significance was indicated as * P<0.05, ** P<0.01, *** P<0.001 and **** P<0.0001 (one-way ANOVA followed by Bonferroni's multiple comparisons post hoc test). ULK1, Unc-51-like kinase 1.
    Hepg2 Human Liver Cancer Cell Line, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/hepg2 human liver cancer cell line/product/ATCC
    Average 99 stars, based on 1 article reviews
    hepg2 human liver cancer cell line - by Bioz Stars, 2026-04
    99/100 stars
    		  Buy from Supplier
    human liver cancer cells hepg2  (ATCC)
    99
    ATCC human liver cancer cells hepg2
    Changes in the basal autophagy flux in different cancer cell lines in response to doxorubicin. <t>HepG2,</t> MCF-7, MDA-MB-231, U87 and normal fibroblast cells were treated with different concentrations of doxorubicin chemotherapy. The level of expression of ULK1, USP20, and P62 was determined via reverse transcription-quantitative PCR. (A-C) Relative expression of ULK1, USP20 and P62 in HepG2 cells. (D-F) Relative expression of ULK1, USP20 and P62 in MCF-7 breast cancer cells. (G-I) Relative expression of ULK1, USP20 and P62 in MDA-MB-231 breast cancer cells. (J-L) Relative expression of ULK1, USP20 and P62 in U87 cells. (M-O) Relative expression of ULK1, USP20 and P62 in normal fibroblast cells. Three repeats were considered for each treatment group. Data are presented as the mean ± SEM. Statistical significance was indicated as * P<0.05, ** P<0.01, *** P<0.001 and **** P<0.0001 (one-way ANOVA followed by Bonferroni's multiple comparisons post hoc test). ULK1, Unc-51-like kinase 1.
    Human Liver Cancer Cells Hepg2, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human liver cancer cells hepg2/product/ATCC
    Average 99 stars, based on 1 article reviews
    human liver cancer cells hepg2 - by Bioz Stars, 2026-04
    99/100 stars
    		  Buy from Supplier
    human liver cancer cell line hepg2  (ATCC)
    99
    ATCC human liver cancer cell line hepg2
    Changes in the basal autophagy flux in different cancer cell lines in response to doxorubicin. <t>HepG2,</t> MCF-7, MDA-MB-231, U87 and normal fibroblast cells were treated with different concentrations of doxorubicin chemotherapy. The level of expression of ULK1, USP20, and P62 was determined via reverse transcription-quantitative PCR. (A-C) Relative expression of ULK1, USP20 and P62 in HepG2 cells. (D-F) Relative expression of ULK1, USP20 and P62 in MCF-7 breast cancer cells. (G-I) Relative expression of ULK1, USP20 and P62 in MDA-MB-231 breast cancer cells. (J-L) Relative expression of ULK1, USP20 and P62 in U87 cells. (M-O) Relative expression of ULK1, USP20 and P62 in normal fibroblast cells. Three repeats were considered for each treatment group. Data are presented as the mean ± SEM. Statistical significance was indicated as * P<0.05, ** P<0.01, *** P<0.001 and **** P<0.0001 (one-way ANOVA followed by Bonferroni's multiple comparisons post hoc test). ULK1, Unc-51-like kinase 1.
    Human Liver Cancer Cell Line Hepg2, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human liver cancer cell line hepg2/product/ATCC
    Average 99 stars, based on 1 article reviews
    human liver cancer cell line hepg2 - by Bioz Stars, 2026-04
    99/100 stars
    		  Buy from Supplier

    Image Search Results


    Changes in the basal autophagy flux in different cancer cell lines in response to doxorubicin. HepG2, MCF-7, MDA-MB-231, U87 and normal fibroblast cells were treated with different concentrations of doxorubicin chemotherapy. The level of expression of ULK1, USP20, and P62 was determined via reverse transcription-quantitative PCR. (A-C) Relative expression of ULK1, USP20 and P62 in HepG2 cells. (D-F) Relative expression of ULK1, USP20 and P62 in MCF-7 breast cancer cells. (G-I) Relative expression of ULK1, USP20 and P62 in MDA-MB-231 breast cancer cells. (J-L) Relative expression of ULK1, USP20 and P62 in U87 cells. (M-O) Relative expression of ULK1, USP20 and P62 in normal fibroblast cells. Three repeats were considered for each treatment group. Data are presented as the mean ± SEM. Statistical significance was indicated as * P<0.05, ** P<0.01, *** P<0.001 and **** P<0.0001 (one-way ANOVA followed by Bonferroni's multiple comparisons post hoc test). ULK1, Unc-51-like kinase 1.

    Journal: Biomedical Reports

    Article Title: Targeting ULK1 and USP20 to modulate autophagy and chemosensitivity in cancer cell lines

    doi: 10.3892/br.2026.2124

    Figure Lengend Snippet: Changes in the basal autophagy flux in different cancer cell lines in response to doxorubicin. HepG2, MCF-7, MDA-MB-231, U87 and normal fibroblast cells were treated with different concentrations of doxorubicin chemotherapy. The level of expression of ULK1, USP20, and P62 was determined via reverse transcription-quantitative PCR. (A-C) Relative expression of ULK1, USP20 and P62 in HepG2 cells. (D-F) Relative expression of ULK1, USP20 and P62 in MCF-7 breast cancer cells. (G-I) Relative expression of ULK1, USP20 and P62 in MDA-MB-231 breast cancer cells. (J-L) Relative expression of ULK1, USP20 and P62 in U87 cells. (M-O) Relative expression of ULK1, USP20 and P62 in normal fibroblast cells. Three repeats were considered for each treatment group. Data are presented as the mean ± SEM. Statistical significance was indicated as * P<0.05, ** P<0.01, *** P<0.001 and **** P<0.0001 (one-way ANOVA followed by Bonferroni's multiple comparisons post hoc test). ULK1, Unc-51-like kinase 1.

    Article Snippet: The following cell lines were involved in the present study and provided from The American Type Culture Collection, human pancreatic cancer cell line PANC-1 (CRL-1469 TM ), Human lung carcinoma-A549 (CRM-CCL-185 TM ), human glioblastoma of unknown origin U-87 MG (HTB-14 TM ), human liver cancer HepG2 (HB-8065 TM ), human breast carcinoma MCF7 (HTB-22 TM ), human breast adenocarcinoma MDA-MB-231 (CRM-HTB-26 TM ), and human normal primary non-immortalized dermal fibroblasts-HDFa (PCS-201-012, https://www.atcc.org/products/pcs-201-012 ).

    Techniques: Expressing, Reverse Transcription, Real-time Polymerase Chain Reaction